Company intelligence / Profile preview
Concenter BioPharma
Tel Mond, Sharon Area, Israelconcenterbiopharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
The company has developed a family of nonsteroidal chemical complexes that have shown efficacy in animal models for treating and preventing type 2 diabetes. Their lead candidate Zygosid-50 is in development.
- Therapeutic areas
- NeurologyEndocrinologyDermatologyPulmonology
- Modalities
- Small moleculesnonsteroidal chemical complexes
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Concenter BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Concenter BioPharma.